Literature DB >> 8613699

Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice.

L Probert1, K Akassoglou, L Alexopoulou, E Douni, S Haralambous, S Hill, G Kassiotis, D Kontoyiannis, M Pasparakis, D Plows, G Kollias.   

Abstract

With increasing awareness that seemingly diverse immune-mediated diseases involve similar pathogenetic mechanisms, and the identification of a growing number of key effector molecules, it is becoming possible to design and generate effective transgenic models for such diseases. Tumor necrosis factor (TNF) plays a prominent role in immune and host defense responses and there is strong evidence that abnormal TNF production contributes to disease initiation and progression in rheumatoid arthritis, systemic inflammatory response syndrome, diabetes, multiple sclerosis, and many other immune-mediated disorders. The generation of TNF transgenic mice, in which TNF production is deregulated, has provided us with direct evidence that, in vivo, this cytokine can indeed trigger the development of such complex disease phenotypes. Transgenic mice that have been engineered to overexpress human or murine TNF molecules in peripheral joints, T cells, or neurons of the central nervous system represent important animal models for human rheumatoid arthritis, systemic inflammation, and multiple sclerosis, respectively. In addition to establishing a central role for TNF in such diseases, these animal models have already proved valuable for identifying additional important disease-effector molecules, and for gaining an insight into the complex in vivo mechanisms that are involved in disease pathogenesis. For example, in the case of arthritis, TNF has been found to transmit its pathogenic effects entirely through interleukin-1, which may therefore represent an additional important target for therapeutic intervention in the human disease. In summary, TNF transgenic models of human disease are expected to serve as important in vivo tools for defining details of disease pathogenesis, potential targets for therapeutic intervention and for evaluating the possible involvement of additional genetic and environmental factors on the disease state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613699     DOI: 10.1002/jlb.59.4.518

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  16 in total

1.  Rapid and sensitive assay of tumor necrosis factor-alpha gene transcription.

Authors:  X Zhang; J Ye; L Wang; J Manosroi; X Shi; Y Rojanasakul
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Soluble TNFRp75 regulates host protective immunity against Mycobacterium tuberculosis.

Authors:  Roanne Keeton; Nasiema Allie; Ivy Dambuza; Brian Abel; Nai-Jen Hsu; Boipelo Sebesho; Philippa Randall; Patricia Burger; Elizabeth Fick; Valerie F J Quesniaux; Bernhard Ryffel; Muazzam Jacobs
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

3.  Constitutive and inducible in vivo protein-DNA interactions at the tumor necrosis factor-alpha promoter in primary human T lymphocytes.

Authors:  C Becker; K Barbulescu; S Wirtz; K H Meyer zum Büschenfelde; S Pettersson; M F Neurath
Journal:  Gene Expr       Date:  1999

Review 4.  RNA-binding proteins in immune regulation: a focus on CCCH zinc finger proteins.

Authors:  Mingui Fu; Perry J Blackshear
Journal:  Nat Rev Immunol       Date:  2016-12-19       Impact factor: 53.106

5.  Tumour necrosis factor-alpha (TNF-alpha) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice.

Authors:  S Wahid; M C Blades; D De Lord; I Brown; G Blake; G Yanni; D O Haskard; G S Panayi; C Pitzalis
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

6.  Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1.

Authors:  Manjula Pandey; Gurol Tuncman; Gökhan S Hotamisligil; Fahumiya Samad
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

7.  Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice.

Authors:  Harini Raghu; Alice Jone; Carolina Cruz; Cheryl L Rewerts; Malinda D Frederick; Sherry Thornton; Jay L Degen; Matthew J Flick
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

8.  Induction of suppressors of cytokine signaling by the trichothecene deoxynivalenol in the mouse.

Authors:  Chidozie J Amuzie; Junko Shinozuka; James J Pestka
Journal:  Toxicol Sci       Date:  2009-07-22       Impact factor: 4.849

9.  Role of astrocytes and chemokine systems in acute TNFalpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappaB and Akt.

Authors:  Marlon P Quinones; Yogeshwar Kalkonde; Carlos A Estrada; Fabio Jimenez; Robert Ramirez; Lenin Mahimainathan; Srinivas Mummidi; Goutam G Choudhury; Hernan Martinez; Lisa Adams; Matthias Mack; Robert L Reddick; Shivani Maffi; Sylva Haralambous; Lesley Probert; Sunil K Ahuja; Seema S Ahuja
Journal:  Mol Cell Neurosci       Date:  2007-09-14       Impact factor: 4.314

10.  Suppression of insulin-like growth factor acid-labile subunit expression--a novel mechanism for deoxynivalenol-induced growth retardation.

Authors:  Chidozie J Amuzie; James J Pestka
Journal:  Toxicol Sci       Date:  2009-10-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.